ALXN2050-MG-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusActive
Effective start/end date4/13/224/19/24

Funding

  • Alexion Pharmaceuticals: $25,488.00